Supplementary Material for: EBV positive lymphoproliferative disorder following lymphodepletion for MAGE A4 adoptive cellular therapy in a patient with synovial sarcoma: Case Report

Lymphoproliferative disorder associated with viral reactivation is a known risk of immunocompromised patients. With development of novel cellular therapies utilizing lymphodepletion regimens in advanced cancer, the risk of lymphoproliferative disorders should be a consideration. Here we report a case of a 61-year-old treated male with history of metastatic synovial sarcoma and multiple treatment lines treated with cell therapy (lymphodepleting chemotherapy and afami-cel, formerly ADP-A2M4, T-cell treatment) on clinical study that developed EBV positive lymphoproliferative disorder (LPD). Patient was treated with rituximab and achieved a complete response. New cellular therapies present promising treatment options for patients and adverse events should be monitored carefully.